Form 4 NEKTAR THERAPEUTICS For: Aug 19 Filed by: Zalevsky Jonathan
Nektar Therapeutics (NKTR)
Last nektar therapeutics earnings: 2/27 04:15 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.nektar.com/investor-relations
Company Research
Source: SEC EDGAR
Impact Snapshot
Event Time:
NKTR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NKTR alerts
Movers & Shakers
The biggest gainers and losers and WHY it moved
NKTR alerts
High impacting Nektar Therapeutics news events
Weekly update
A roundup of the hottest topics
NKTR
News
- Nektar Therapeutics (NASDAQ: NKTR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $6.50 price target on the stock.MarketBeat
- Nektar Therapeutics Announces Completion of Target Enrollment in REZOLVE-AD Phase 2b Clinical Trial of Rezpegaldesleukin in Patients with Moderate-to-Severe Atopic DermatitisPR Newswire
- Nektar Therapeutics (NASDAQ: NKTR) was upgraded by analysts at B. Riley to a "strong-buy" rating.MarketBeat
- Nektar Therapeutics (NASDAQ: NKTR) is now covered by analysts at B. Riley. They set a "buy" rating and a $4.00 price target on the stock.MarketBeat
- Nektar Therapeutics (NASDAQ: NKTR) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $6.50 price target on the stock.MarketBeat
NKTR
Earnings
- 11/7/24 - Beat
NKTR
Sec Filings
- 1/17/25 - Form 5
- 1/17/25 - Form 5
- 1/17/25 - Form 5
- NKTR's page on the SEC website